Yazarlar : Jacobsen E, Pozdnyakova O, Redd R

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/imatinib-mesylate-lacks-efficacy-relapsed-refractory-peripheral-t-cell-lymphoma?tsid=5

Konu : Lenfoma

Literatür İçeriği :  ABSTRACT Platelet derived growth factor alpha (PDGFR- α) is expressed in PTCL, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T NHL. PDGFR- α expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1-PDGFR- α fusion and/or PDGFR- α amplification were not required for study entry. We documented no objective responses. The median progression free survival was 21.0 days (90% CI (15.0, 28.0) and the median overall survival was 154 days (90% CI (35, 242). Four patients had tissue available for analysis of PDGFR- α by immunohistochemistry and three of these patient's tumors expressed PDGFR- α. Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR- α expression was not required for study entry.

Literatür Arşivi